Reaktionsgleichung
Cl[C:2]1[CH:7]=[C:6]([C:8]2[CH:13]=[CH:12][C:11]([S:14][C:15]3[CH:20]=[CH:19][CH:18]=[CH:17][C:16]=3[O:21][CH3:22])=[C:10]([C:23]([F:26])([F:25])[F:24])[CH:9]=2)[CH:5]=[CH:4][N:3]=1.OC1CCNC1.[CH3:33][N:34]([CH3:44])[CH2:35][CH2:36][CH2:37][N:38]1[CH2:43][CH2:42][NH:41][CH2:40][CH2:39]1>>[CH3:22][O:21][C:16]1[CH:17]=[CH:18][CH:19]=[CH:20][C:15]=1[S:14][C:11]1[CH:12]=[CH:13][C:8]([C:6]2[CH:5]=[CH:4][N:3]=[C:2]([N:41]3[CH2:42][CH2:43][N:38]([CH2:37][CH2:36][CH2:35][N:34]([CH3:33])[CH3:44])[CH2:39][CH2:40]3)[CH:7]=2)=[CH:9][C:10]=1[C:23]([F:26])([F:25])[F:24]Komponenten
4
Edukt 3
Produkt 1
Versuchsvorschrift
The title compound was prepared according to the procedures of Example 38E, substituting compound 76 with compound 96 (0.039 g, 0.0985 mmol) and 3-hydroxypyrrolidine with 1-(3-dimethylaminopropyl)piperazine. A yellow solid 113 was obtained (0.0414 g, 79%). 1H NMR (CDCl3, 400 MHz) δ 2.20-2.50 (br, 6H), 2.42-2.50 (m, 2H), 2.86 (s, 6H), 3.21-3.28 (m, 2H), 3.32-3.38 (br, 2H), 3.83 (s, 3H), 4.05-4.10 (br, 2H), 6.88 (s, 1H), 6.99-7.06 (m, 3H), 7.10 (d, J=8.2 Hz, 1H), 7.43-7.52 (m, 3H), 7.85 (s, 1H), 8.25 (d, J=5.5 Hz, 1H); MS (APCI) m/z 531 (M+H)+.
Quellen und Nachweise
- ORD-Eintrag
- ord-4a0f4150681d429f8249d8445f0d07bc
- Quelldatensatz
- uspto-grants-2004_09
- Patentnummer
- US06787542B2
Verknüpfte Notizen
Wird geladen…